Mr. Chairmen and members of the Subcommittee on Standards and Security, the Accredited Standards Committee (ASC) X12, Health Level Seven (HL7) and the National Council for Prescription Drug Programs (NCPDP) thank you for the opportunity to testify today on the subject of the Standards Development Organization (SDO) process and how it works within the regulatory environment. My name is Lynne Gilbertson and I am speaking today on behalf of the joint SDO initiative to improve the standards adoption process under HIPAA. A Health Level Seven (HL7) representative was unable to attend todays meeting.
The testimony delivered today on behalf of ASC X12, HL7 and NCPDP is a continuation of the December 2005 testimony each individual SDO provided on this topic. In October 2006 the SDOs presented a final unified testimony on this subject.
In October 2006, we presented recommendations in the document entitled Proposal for the Modification of the HIPAA Transaction Standards Adoption Process. This document represents the SDO unified approach to streamlining the HIPAA standards adoption process. This joint SDO prepared document examines the current process for adopting transaction standards, summarizes findings, and proposes ways to improve the adoption process that results in increased efficiency. The joint SDO proposal was approved by all three SDOs and the approaches we recommend can and will be implemented by us should HHS elect to adopt this streamlined approach. Minor modifications were requested by the Committee; these updates were made and the final document sent to the Committee.
In order to maximize the time for us to engage in a more productive discussion with the Subcommittee and the Reactor Panel on this topic weve elected to keep our verbal testimony brief.
The Current Process:
Operating in the regulatory environment, the ability of the Standards Development Organizations to be responsive to industry need is greatly impaired, resulting in stakeholders waiting a minimum of 5 years to be able to implement new specifications adopted under HIPAA. Please refer to section 4 Problems with the existing HIPAA Transaction Implementation Specifications adoption process for additional information.
Most concerning are the underlying industry assumptions
The regulatory process is not predictable (when it begins or ends), is potentially very lengthy, and compromises the ability of the SDO to be responsive to industrys business requirements.
The Proposed Solution:
This proposal retains many of the existing processes. It also offers a more efficient approach to several of the key areas where current problems exist. Opportunities for input and participation are not eliminated. Rather, efficiency is achieved by consolidating public participation and input at the appropriate time. Additionally, we propose adding steps that are critical to the process, such as the development of a benefit analysis report, requested by the Office of e-Health Standards and Services (OESS).
Streamlined process Highlights:
With these process improvements important benefits are reached.
ASC X12, HL7 and NCPDP thank you for the opportunity to offer these collaborative recommendations on improving this important process. We have spent considerable time understanding the process, assessing the impacts, and building recommendations. We firmly believe that action needs to be taken at the federal or congressional level for changes to occur that will allow us to be responsive and supportive of industry business needs in a predictable and timely manner. We look forward to further discussing our recommendations with the NCVHS and OESS to affect change on this important issue.
We would like to thank the Subcommittee for the opportunity to testify today. We welcome any questions you may have.
About Accredited Standards Committee X12
ASC X12 (http://www.x12.org/) develops, maintains, interprets, publishes and promotes the proper use of American National and UN/EDIFACT International Electronic Data Interchange Standards. The ASC X12 body comes together three times each year to develop and maintain EDI standards. Its main objective is to develop standards to facilitate electronic interchange relating to such business transactions as order placement and processing, shipping and receiving information, invoicing, and payment and cash application data, and data to and from entities involved in finance, insurance, education, and state and federal governments. Together, committee members develop and promote EDI standards that streamline business transactions. X12 standards facilitate these transactions by establishing a common, uniform business language for computers to communicate across town or around the world. With more than 275 transaction sets, X12 standards can be used to electronically conduct nearly every facet of business-to-business operations.
About Health Level Seven
Founded in 1987, Health Level Seven, Inc. (http://www.HL7.org/) is a not-for-profit, ANSI-accredited standards developing organization dedicated to providing a comprehensive framework and related standards for the exchange, integration, sharing, and retrieval of electronic health information that supports clinical practice and the management, delivery and evaluation of health services. HL7's more than 2,000 members represent approximately 500 corporate members, including 90 percent of the largest information systems vendors serving healthcare.
About the National Council for Prescription Drug Programs
NCPDP (http://www.ncpdp.org/) is a non-profit ANSI-accredited Standards Development Organization consisting of more than 1,500 members who represent computer companies, drug manufacturers, pharmacy chains and independents, drug wholesalers, insurers, mail order prescription drug companies, pharmaceutical claims processors, physician services organizations, prescription drug providers, software vendors, telecommunication vendors, service organizations, government agencies and other parties interested in electronic standardization within the pharmacy services sector of the health care industry.